Therapy
Inebilizumab
Humanised IgG1κ anti-CD19 mAb with afucosylation (enhanced NK ADCC): targets ALL CD19+ cells including naive B cells, GC B cells, memory B cells, AND PLASMABLASTS (CD20-negative, CD19+).
Also called: Uplizna, anti-CD19, CD19 depletion
In short
- 1What it is: a therapy in therapies and applications.
- 2How it connects: acts on 2 and is affected by 1 concepts — mostly 1 receptor, 1 disease, 1 trial.
- 3Where it sits: therapy, trial on the 15-step immune chain.
What it does
MITIGATE trial (IgG4-related disease, N=135): inebilizumab 87% flare reduction vs 39% placebo (primary endpoint met) → FDA approved IgG4-RD 2025.
Its connections at a glance
Each dot is a concept directly linked to Inebilizumab. Colours show the kind of concept.
Sources & evidenceloading…
Loading reviewed sources…
Graph ID I019 · concept status: established. Select any connection above to inspect evidence for that specific link.